Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival

Journal of the National Cancer Institute

Volumn 109, Issue 6, 2017, Pages

  Lee, Chee Khoon ^a,b   Davies, Lucy ^a   Wu, Yi Long ^c   Mitsudomi, Tetsuya ^d   Inoue, Akira ^e   Rosell, Rafael ^f   Zhou, Caicun ^g   Nakagawa, Kazuhiko ^d   Thongprasert, Sumitra ^h   Fukuoka, Masahiro ^d   Lord, Sally ^a,i   Marschner, Ian ^a,j   Tu, Yu Kang ^k   Gralla, Richard J ^l   Gebski, Val ^a   Mok, Tony ^m   Yang, James Chih Hsin ^k,n  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ST GEORGE HOSPITAL   (Australia)

^c GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^d KINKI UNIVERSITY   (Japan)

^e TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^g TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^h Faculty of Medicine Chiang Mai University   (Thailand)

ⁱ University of Norte Dame   (Australia)

^j MACQUARIE UNIVERSITY   (Australia)

^k NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^l ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^m CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

ⁿ NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GENETICS; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; ETHNICITY; EXON; FOLLOW UP; GENE DELETION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; META ANALYSIS; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PATIENT CODING; PEOPLE BY SMOKING STATUS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TASK PERFORMANCE; CARCINOMA, NON-SMALL-CELL LUNG; COMPARATIVE STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; GENETICS; LUNG NEOPLASMS; NUCLEOTIDE SEQUENCE; RETREATMENT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BASE SEQUENCE; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; ERLOTINIB HYDROCHLORIDE; EXONS; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETREATMENT; SEQUENCE DELETION;

EID: 85027265241     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djw279     Document Type: Article

References (26)

1. Wu YL, Zhou C, Liam CK, et al. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: Analyses from the phase III, randomized, open-label, ENSURE study. Ann Oncol. 2015;26(9):1883-1889.
2. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239-246.
3. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947-957.
4. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362(25): 2380-2388.
5. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-smallcell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12(8):735-742.
6. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol. 2010;11(2):121-128.
7. Sequist LV, Yang JCH, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31(27):3327-3334.
8. Wu YL, Zhou C, Hu CP, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): An open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(2):213-222.
9. Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results froma phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011;29(21):2866-2874.
10. Inoue A, Kobayashi K, Maemondo M, et al. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol. 2013;24:54-59.
11. Zhou C, Wu YL, Chen G, et al. Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802). Ann Oncol. 2015;26(9):1877-1883.
12. Mitsudomi T, Morita S, Yatabe Y, et al. Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with nonsmall cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR). J Clin Oncol. 2012;30(15-suppl):7521.
13. Yang JCH, Wu YL, Schuler M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): Analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015;16(2):141-151.
14. Mok T, Yang JJ, Lam KC. Treating patients with EGFR-sensitizing mutations: First line or second line-is there a difference? J Clin Oncol. 2013;31(8): 1081-1088.
15. Lee CK, Wu YL, Ding PN, et al. Impact of specific epidermal growth factor receptor (EGFR) mutations and clinical characteristics on outcomes after treatment with EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR-mutant lung cancer: A meta-analysis. J Clin Oncol. 2015;33(17): 1958-1965.
16. Kleinbaum D, Klein M. Survival Analysis. 2nd ed. New York: Springer; 2005.
17. Gleser LJ, Olkin I. Models for estimating the number of unpublished studies. Stat Med. 1996;15(23):2493-2507.
18. Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361(10):958-967.
19. Lee CK, Brown C, Gralla RJ, et al. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: A meta-analysis. J Natl Cancer Inst. 2013;105(9):595-605.
20. Takano T, Fukui T, Ohe Y, et al. EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: A historical comparison of patients treated before and after gefitinib approval in Japan. J Clin Oncol. 2008;26(34):5589-5595.
21. Booth CM, Eisenhauer EA. Progression-free survival: Meaningful or simply measurable? J Clin Oncol 2012;30(10):1030-1033.
22. Blumenthal GM, Karuri SW, Zhang H, et al. Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: A US Food and Drug Administration trial-level and patient-level analyses. J Clin Oncol. 2015;33(9): 1008-1015.
23. Dodd LE, Korn EL, Freidlin B, et al. Blinded independent central review of progression-free survival in phase III clinical trials: Important design element or unnecessary expense? J Clin Oncol. 2008;26(22):3791-3796.
24. Chen G, Feng J, Zhou C, et al. Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC). Ann Oncol. 2013;24(6):1615-1622.
25. Oizumi S, Kobayashi K, Inoue A, et al. Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: Quality of life analysis of North East Japan Study Group 002 Trial. Oncologist. 2012;17(6):863-870.
26. Thongprasert S, Duffield E, Saijo N, et al. Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from asia with advanced NSCLC (IPASS). J Thorac Oncol. 2011;6(11):1872-1880.